Clinical Application of TKD-36 (Moku-boi-to) on Chronic Heart Failure in Dogs.

DOI Web Site 9 References
  • KOYAMA Hidekazu
    Department of Veterinary Internal Medicine, Nippon Veterinary and Animal Science University
  • TAKEMURA Naoyuki
    Department of Veterinary Internal Medicine, Nippon Veterinary and Animal Science University
  • MOTOYOSHI Shigekatsu
    Department of Veterinary Internal Medicine, Nippon Veterinary and Animal Science University

Bibliographic Information

Other Title
  • 犬の慢性心不全に対するＴＤＫ‐３６（木防い湯）の臨床応用
  • イヌ ノ マンセイ シンフゼン ニ タイスル TKD-36 モクボイトウ ノ

Search this article

Abstract

A multi-central clinical trial was conducted to assess the effect of TKD-36 (Moku-boi-to)on chronic heart failure in dogs. TKD-36 (75, 150 or 300 mg/kg/day, divided b. i. d., p. o.) or placebo were administered for 4 weeks to dogs showing signs of chronic heart failure. Overall assessment and various clinical evaluation of clinical symptoms in dogs treated with TKD-36 (150 and 300 mg/kg/day) were excellent compared to that in dogs treated with the placebo. But the dose of 75 mg/kg/day of TKD-36 did not improve any clinical signs of heart failure as same as the placebo group. No adverse reactions attributable to TKD-36 administration were observed, confirming its safety in this species. Based on efficacy, safety and overall assessment analyses, the optimal dosage of TKD-36 is from 150 to 300 mg/kg/day.<BR>These results clearly indicate that TKD-36 is an excellent drug for a treatment of the chronic heart failure in dogs.

Journal

References(9)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top